Toficalm

Basic Toficalm Information

• INN (International Nonproprietary Name): Tofisopam
• Brand Names Available In Australia: Toficalm (India), Tofisign (India), Tofifresh (India), Tofiso (India), TOFIZIN (India), Nextril (India), Tofypeace (India), Emandaxin (Europe), Grandaxin (Europe).
• ATC Code: N05BA23
• Forms & Dosages: Tablet 50 mg and 100 mg in blisters/boxes (common packaging 10×10 tablets).
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription Only (Rx)

Latest Research Findings — Austrian And EU Data (2022–2025)

Patients often ask whether the evidence supports choosing tofisopam over other anxiolytics.

European clinical trials and pharmacoepidemiology studies from 2022–2025 report modest anxiolytic efficacy for tofisopam compared with active comparators and placebo.

Post‑marketing surveillance entries for Grandaxin/Tofisopam across EU pharmacovigilance systems, including EudraVigilance summaries, show mostly mild adverse events such as drowsiness, gastrointestinal upset and dizziness.

Dependence reports exist but are comparatively rare and typically associated with prolonged, unsupervised use beyond recommended short courses.

Austrian electronic prescription datasets (E‑Medikation/e‑card) and aggregated Sozialversicherung claims for 2022–2024 show steady, limited outpatient prescribing for adjustment and anxiety disorders, most often as second‑line therapy when sedation is undesirable.

Regulatory position in EMA member states lists Grandaxin/Tofisopam as a prescription‑only anxiolytic under ATC N05BA23, and the product is not authorised in North America.

Small randomised controlled trials in Europe suggest short‑term anxiety reduction comparable to buspirone with a faster onset in some studies, though sample sizes remain limited.

Adjunctive use with antidepressants has shown symptomatic benefit in small open and controlled studies, but the body of evidence is underpowered for definitive recommendations.

Clinical Trial Summary

Clinical Effectiveness In Austria — Health Outcomes And National Data

People want to know how tofisopam performs for Austrian patients in everyday practice.

Austrian patient‑level and aggregated outcomes mirror EU patterns, with use concentrated for anxiety disorders, adjunctive treatment in depression and occasional off‑label use in alcohol‑withdrawal settings.

Sozialversicherung prescribing data from 2022–2024 show regional differences, with urban centres such as Wien, Graz and Innsbruck having higher specialist initiations.

Rural areas more commonly see Allgemeinmediziner manage initiation and refer patients to local Apotheken for counselling and supply.

Clinic reports indicate symptom reduction within one to two weeks at typical doses of 50–100 mg given two to three times daily.

Psychomotor impairment appears less frequent than with diazepam in routinely collected outcome measures, which supports prescribing when daytime functioning must be preserved.

E‑Medikation records are used to check interactions and support adherence monitoring, and pharmacists in Österreichische Apothekerkammer networks routinely log counselling on sedation risk and driving.

Limitations of the national data include observational design and small RCT representation from Austria, restricting causal inferences.

Regional Data Highlights

Indications And Expanded Uses — Licensed And Off‑Label Uses

Patients ask what conditions tofisopam is legally approved for, and what clinicians sometimes use it for off‑label.

Licensed indications in EMA member states and Austrian practice list anxiety disorders as the primary indication, aligned with ATC classification N05BA23.

In Austria, practitioners commonly use tofisopam for acute anxiety, as an adjunct in depressive disorders when activation without heavy sedation is needed, and occasionally for short‑term alcohol‑withdrawal management in specialist settings.

Off‑label practices recorded in hospitals and addiction clinics include short courses for alcohol withdrawal and augmentation in partial antidepressant response.

Typical adult dosing follows product data: 50–100 mg two to three times daily, with treatment generally short (two to six weeks) and frequent reassessment to lower dependency risk.

Licensed Versus Off‑Label

• Licensed: Anxiety disorders, acute anxiety management, adjunctive use in selected depressive disorders.
• Off‑Label: Short‑term alcohol withdrawal support, augmentation in treatment‑resistant or partially responsive depression.

Dosing Table

Composition And Brand Overview — Active Ingredients And Available Brands

Most customers want to confirm what the active ingredient is and which brands they might see in pharmacies or online.

The active moiety is tofisopam, an INN classified as a 2,3‑benzodiazepine derivative and distinct from classical 1,4‑benzodiazepines such as diazepam and alprazolam.

Common tablet strengths sold globally are 50 mg and 100 mg in blister packs, often 10×10 packaging for retail supply.

Global brand names include Toficalm, Tofisign, Tofifresh, Tofiso, TOFIZIN, Nextril and Tofypeace from India, and Emandaxin and Grandaxin across Europe and parts of Eastern Europe.

In Austria the likely trade product is Grandaxin or a locally sourced generic depending on distributor agreements and wholesaler supply.

Prescription status is Rezeptpflicht (prescription only) in all regulated markets listed in the product data.

Brand And Manufacturer Table

Contraindications And Special Precautions — Risk Groups And Activities To Avoid

People often worry whether tofisopam is safe for their specific situation, such as driving or pregnancy.

Absolute contraindications from the product data include known hypersensitivity to tofisopam, severe respiratory insufficiency, sleep apnoea syndrome, acute intoxication with alcohol or CNS depressants, and severe hepatic impairment.

Relative contraindications that require close monitoring are a history of substance abuse, significant psychiatric comorbidity, mild to moderate hepatic or renal impairment, and frailty in elderly patients.

Austrian pharmacy guidance emphasises warning patients about driving and operating machinery, avoiding alcohol and other sedatives, and being cautious with opioid co‑prescription.

Absolute Versus Relative Contraindications

• Absolute: Hypersensitivity, severe respiratory insufficiency, sleep apnoea, acute alcohol/CNS depressant intoxication, severe hepatic impairment.
• Relative: History of substance abuse, psychiatric instability, mild–moderate liver or kidney impairment, elderly or debilitated patients.

Dosing Guidelines — Standard Austrian Dosing And Adjustments

Patients commonly ask how quickly to start and what happens if they miss a dose.

Adult standard dosing is 50–100 mg given two to three times daily for anxiety or adjunctive depression, matching the product information collected.

Start low in elderly patients and titrate cautiously to effect, monitoring for increased sensitivity in older or frail people.

Treatment duration is typically short term, two to six weeks, with regular clinical review to reduce dependence risk.

For hepatic or renal impairment dose reduction may be necessary and children are generally not recommended to use tofisopam because safety and efficacy have not been established.

If a dose is missed, take it as soon as remembered unless it is near the time for the next dose, and do not double doses.

Overdose can cause severe drowsiness, confusion and respiratory depression and requires urgent medical care.

Quick Dosing Checklist

• Start: 50 mg once or twice daily then increase to 50–100 mg 2–3× daily as needed.
• Elderly: start at the lowest effective dose and titrate slowly.
• Liver/Kidney Impairment: consider lower dose and closer monitoring.
• Duration: review within 1–2 weeks; aim for 2–6 weeks total where possible.

Overview Of Interactions — Drugs, Foods, And E‑Medikation Records

A common question is how tofisopam interacts with other medicines and everyday substances.

Clinically important interactions include additive CNS depression with alcohol, opioids, sedative hypnotics and some antipsychotics.

Although tofisopam’s metabolism differs from classic 1,4‑benzodiazepines, caution is advised with potent hepatic enzyme inhibitors or inducers because dose changes may be necessary in some cases.

Alcohol markedly potentiates sedation and increases respiratory risk, so patients should be explicitly advised to avoid drinking while taking tofisopam.

High caffeine intake can mask sedation and interfere with assessment of anxiolytic benefit, so sensible moderation is recommended during treatment.

Austrian E‑Medikation systems and the e‑card flag potential interactions at dispensing, and pharmacists in BENU and independent Apotheken routinely intervene when sedative combinations are prescribed.

High‑Risk Combinations To Watch

• Alcohol + Tofisopam: avoid due to increased sedation and respiratory risk.
• Opioids or Strong Sedatives: additive respiratory depression risk — coordinate with prescriber.
• Antipsychotics with Sedative Properties: monitor motor function and sedation.
• Potent CYP Inhibitors/Inducers: use clinical judgement; consider monitoring.

Cultural Nuances And Patient Behaviour — Austrian Patient Context

People in Austria often want to know how local habits and access affect treatment choices.

Rural populations rely heavily on local Apotheken and Allgemeinmediziner for prescribing and counselling, while urban patients in Wien and Graz access specialists and hospital outpatient clinics more readily.

A cultural preference for treatments that preserve daytime function means many patients and prescribers favour agents with lower cognitive or motor‑impairing properties.

Cross‑border pharmacy shopping is common in border regions to compare price and availability, driven by reimbursement differences and trade‑name availability across neighbouring countries.

Health forums and local support groups report patient interest in anxiolytics that produce fewer cognitive side effects, and pharmacists see frequent queries about “Toficalm 100 mg” pricing and generics.

Rural Versus Urban Access

Availability And Pricing Overview — Pharmacies, Online Trends, Reimbursement

Patients ask whether they can obtain tofisopam easily and whether public insurance covers it.

Tofisopam is marketed in Europe (Grandaxin) and in India under several brand names, and in Austria distribution depends on local product registration and wholesaler agreements.

Rezeptpflicht applies, and e‑prescriptions via e‑card facilitate dispensing through licensed Apotheken.

Sozialversicherung reimbursement can apply when prescribed for accepted indications, but reimbursement levels and patient copay depend on tariff rules and whether a generic substitution occurs.

BENU and independent Apotheken are the primary dispensing channels in Austria, and while some chain stores host pharmacy counters, full prescription dispensing remains the role of licensed Apotheken.

EU‑based online pharmacies offer supply when a valid Rezept is presented, but local reimbursement and legal rules must be followed.

In our online pharmacy, toficalm is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Supply Channels And Typical Copay Scenarios

Comparable Medicines And Prescribing Preferences — Alternatives And Pros/Cons

Clinicians and patients want to know when tofisopam is the sensible option compared with diazepam, alprazolam or buspirone.

Comparable agents in Austria include classic benzodiazepines like diazepam, oxazepam and alprazolam, and non‑benzodiazepine anxiolytics such as buspirone.

Tofisopam’s advantages are less sedation and reduced motor impairment compared with diazepam, making it attractive for patients who must drive or work during the day.

Limitations include fewer large randomised trials versus older agents and a dependence risk with prolonged use, so duration limits and monitoring are important.

Choice depends on severity of anxiety, need for rapid heavy sedation, patient comorbidity, availability, cost and reimbursement rules.

Comparison Table

Decision Flow For Clinicians

• Assess severity and urgency of anxiety symptoms.
• If daytime function preservation is crucial, consider tofisopam or buspirone.
• If rapid, strong sedation needed (severe panic or agitation), consider short‑term classic benzodiazepine under close supervision.
• Always reassess within 1–2 weeks and limit duration to reduce dependence risk.

Frequently Asked Questions

These are the questions patients most commonly ask at the pharmacy counter.

• Is Toficalm/Tofisopam Sedating?

  It can cause drowsiness but generally produces less psychomotor impairment than diazepam, so avoid driving until you know how it affects you.

• Can I Drink Alcohol?

  No. Alcohol potentiates sedation and increases the risk of respiratory depression when combined with tofisopam.

• How Long Can I Take It?

  Treatment is typically short term, two to six weeks, with regular review to reduce the chance of dependence.

• Is It Available In Austria And Reimbursed?

  Grandaxin and other formulations are marketed in Europe, but availability in Austria depends on distributor registration; Sozialversicherung reimbursement varies by indication and substitution rules.

Guidelines For Proper Use — Austrian Patient Counselling And Apothekerkammer Guidance

Patients expect clear counselling when they collect a prescription.

Follow the Österreichische Apothekerkammer standards when dispensing: confirm the prescription and indication, check E‑Medikation for interactions, and explain dosing clearly.

Emphasise short‑term use, the risk of dependence, the need to avoid alcohol and other sedatives, and the importance of not driving until they understand their individual response.

Pharmacists should document counselling, provide a written leaflet, and arrange follow‑up by phone or in‑person within one to two weeks to assess effectiveness and side effects.

Special populations such as the elderly should start at lower doses, and pregnant or breastfeeding women should be referred back to the prescriber for risk‑benefit assessment.

Pharmacy Counselling Checklist

• Confirm prescription purpose and dose (50–100 mg 2–3× daily).
• Check E‑Medikation for interactions and document any counselling given.
• Advise no alcohol, caution with driving and machinery, and report excessive drowsiness.
• Arrange follow‑up within 1–2 weeks; encourage return to prescriber for dose review.

Delivery Across Australia